You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

514 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant
May 2019
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Jun 2019
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Sep 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    regorafenib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC) according to clinical criteria
Aug 2023
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019

Pages